Literature DB >> 19267956

Influence of prefrontal target region on the efficacy of repetitive transcranial magnetic stimulation in patients with medication-resistant depression: a [(18)F]-fluorodeoxyglucose PET and MRI study.

Marie-Laure Paillère Martinot1, André Galinowski, Damien Ringuenet, Thierry Gallarda, Jean-Pascal Lefaucheur, Frank Bellivier, Christine Picq, Pascale Bruguière, Jean-François Mangin, Denis Rivière, Jean-Claude Willer, Bruno Falissard, Marion Leboyer, Jean-Pierre Olié, Eric Artiges, Jean-Luc Martinot.   

Abstract

It is currently unknown whether the antidepressant effect of repetitive transcranial magnetic stimulation (rTMS) depends on specific characteristics of the stimulated frontal area, such as metabolic changes. We investigated the effect of high-frequency rTMS, administered over the most hypometabolic prefrontal area in depressed patients in a two-site, double-blind, randomized placebo-controlled add-on study. Forty-eight patients with medication-resistant major depression underwent magnetic resonance imaging and [(18)F]-fluorodeoxyglucose positron emission tomography (PET) in order to determine a target area for rTMS. After randomization to PET-guided (n = 16), standard (n = 18), or sham rTMS (n = 14) conditions, the patients received 10 sessions of 10-Hz rTMS (1600 pulses/session) at 90% motor threshold. Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) scores did not differ between PET-guided, standard and sham groups at 2-wk end-point. Exploratory comparison of left PET-guided (n = 9), right PET-guided, standard, and sham rTMS revealed significant effects. The highest improvement in MADRS scores was observed with left PET-guided (60 + or - 31%), significantly superior to sham (30 + or - 37%, p = 0.01) and right-guided (31 + or - 33%, p = 0.02) stimulation. Comparison between left PET-guided and standard rTMS (49 + or - 28%) was not significant (p = 0.12). Comparison between stimulation over dorsolateral prefrontal cortex (BA 9-46), stimulation of other areas, and sham rTMS was statistically significant. Stimulation over BA 9-46 region (n = 15) was superior to sham rTMS (p = 0.02). The results do not support the general hypothesis of increased antidepressant effects of high-frequency rTMS with prefrontal hypometabolism-related PET guidance. Nonetheless, whether metabolism and anatomy characteristics of left frontal area underneath the coil might account for an increase or speeding up of rTMS effects needs further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19267956     DOI: 10.1017/S146114570900008X

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  25 in total

1.  Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression.

Authors:  Alexander McGirr; Sneha Karmani; Rashmi Arsappa; Marcelo T Berlim; Jagadisha Thirthalli; Kesavan Muralidharan; Lakshmi N Yatham
Journal:  World Psychiatry       Date:  2016-02       Impact factor: 49.548

2.  Changes in dorsolateral prefrontal connectivity after rTMS in treatment-resistant depression: a brain perfusion SPECT study.

Authors:  Raphaëlle Richieri; Damien Jouvenoz; Antoine Verger; Patrick Fiat; Laurent Boyer; Christophe Lançon; Eric Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-03       Impact factor: 9.236

3.  Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression in Adult and Youth Populations: A Systematic Literature Review and Meta-Analysis.

Authors:  Laura E Leggett; Lesley J J Soril; Stephanie Coward; Diane L Lorenzetti; Gail MacKean; Fiona M Clement
Journal:  Prim Care Companion CNS Disord       Date:  2015-11-05

4.  Baseline brain metabolism in resistant depression and response to transcranial magnetic stimulation.

Authors:  Marie-Laure Paillère Martinot; Jean-Luc Martinot; Damien Ringuenet; André Galinowski; Thierry Gallarda; Frank Bellivier; Jean-Pascal Lefaucheur; Hervé Lemaitre; Eric Artiges
Journal:  Neuropsychopharmacology       Date:  2011-08-17       Impact factor: 7.853

5.  Prospective Validation That Subgenual Connectivity Predicts Antidepressant Efficacy of Transcranial Magnetic Stimulation Sites.

Authors:  Anne Weigand; Andreas Horn; Ruth Caballero; Danielle Cooke; Adam P Stern; Stephan F Taylor; Daniel Press; Alvaro Pascual-Leone; Michael D Fox
Journal:  Biol Psychiatry       Date:  2017-11-10       Impact factor: 13.382

6.  Anatomically based targeting of prefrontal cortex for rTMS.

Authors:  Tal Herbsman; Ziad Nahas
Journal:  Brain Stimul       Date:  2011-02-04       Impact factor: 8.955

7.  Dorsolateral prefrontal γ-aminobutyric acid in patients with treatment-resistant depression after transcranial magnetic stimulation measured with magnetic resonance spectroscopy

Authors:  Jennifer G. Levitt; Guldamla Kalender; Joseph O’Neill; Joel P. Diaz; Ian A. Cook; Nathaniel Ginder; David Krantz; Michael J. Minzenberg; Nikita Vince-Cruz; Lydia D. Nguyen; Jeffry R. Alger; Andrew F. Leuchter
Journal:  J Psychiatry Neurosci       Date:  2019-11-01       Impact factor: 6.186

8.  Identification of reproducible individualized targets for treatment of depression with TMS based on intrinsic connectivity.

Authors:  Michael D Fox; Hesheng Liu; Alvaro Pascual-Leone
Journal:  Neuroimage       Date:  2012-11-07       Impact factor: 6.556

Review 9.  Measuring and manipulating brain connectivity with resting state functional connectivity magnetic resonance imaging (fcMRI) and transcranial magnetic stimulation (TMS).

Authors:  Michael D Fox; Mark A Halko; Mark C Eldaief; Alvaro Pascual-Leone
Journal:  Neuroimage       Date:  2012-03-19       Impact factor: 6.556

10.  Cortical folding in patients with bipolar disorder or unipolar depression.

Authors:  Jani Penttilä; Marie-Laure Paillère-Martinot; Jean-Luc Martinot; Damien Ringuenet; Michèle Wessa; Josselin Houenou; Thierry Gallarda; Frank Bellivier; André Galinowski; Pascale Bruguière; François Pinabel; Marion Leboyer; Jean-Pierre Olié; Edouard Duchesnay; Eric Artiges; Jean-François Mangin; Arnaud Cachia
Journal:  J Psychiatry Neurosci       Date:  2009-03       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.